AstraZeneca: Externally Sponsored Scientific Research (ESR) – Cross-TA AI & Digital Focus
AstraZeneca’s AI/Digital ESR initiative funds investigator-driven projects that harness artificial intelligence, machine learning, and digital health tools across therapeutic areas to improve patient awareness, early diagnosis, adherence, and post-treatment wellbeing.
Eligibility Criteria:
-
External teams with AI/digital-health expertise in academic, clinical, or industry settings.
-
Proposals must address one of five strategic pillars—patient awareness, early diagnosis, treatment adherence & AE management, post-treatment monitoring, or wellbeing—and align with data-privacy and regulatory requirements.
Funding Details:
-
Support Type: Software licenses, algorithm validation data, pilot-deployment resources, and digital-endpoint integration support.
-
Areas of Interest:
-
Patient Awareness: Digital engagement platforms, bias-mitigation in AI/ML, decentralized trial recruitment, PRO integration.
-
Early Diagnosis: Novel screening algorithms (ctDNA, radiomics), primary-care digital tools, digital biomarkers.
-
Treatment & AE Management: AI-driven monitoring of symptoms and adverse events, digital adherence solutions, QOL-endpoint digitalization.
-
Post-Treatment Monitoring: Remote-monitoring systems, personalized post-market surveillance models.
-
Wellbeing: Digital therapeutics for patient empowerment, data-driven communication frameworks.
-
Deadline:
Continuous intake; submit via ESR portal with “[email protected]” username format.
Where to Go for Further Information:
Download the Cross-TA AI/Digital ESR Handbook from AstraZeneca’s Open Innovation site and register for portal access.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023